tiprankstipranks
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
US Market

Allogene Therapeutics (ALLO) Income Statement

Compare
1,385 Followers

Allogene Therapeutics Income Statement

Last quarter (Q3 2024), Allogene Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Allogene Therapeutics's net income was $-66.29M. See Allogene Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 95.00K$ 243.00K$ 38.49M$ 0.00$ 0.00
Gross Profit
$ -242.82M$ -16.48M$ 25.42M$ -11.54M$ -5.03M
Operating Expenses
$ 327.83M$ 335.69M$ 294.28M$ 258.24M$ 202.01M
Depreciation and Amortization
$ 14.20M$ 14.29M$ 10.45M$ 11.54M$ 5.03M
EBITDA
$ -300.29M$ -321.24M$ -169.74M$ -250.81M$ -179.90M
Operating Income
$ -327.74M$ -335.45M$ -255.79M$ -258.24M$ -202.01M
Other Income/Expenses
$ 472.00K$ -4.88M$ -1.86M$ 8.02M$ 17.08M
Pretax Income
$ -327.26M$ -332.63M$ -257.00M$ -250.22M$ -184.93M
Net Income
$ -327.26M$ -329.81M$ -244.84M$ -233.47M$ -184.59M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -2.09$ -2.30$ -1.80$ -1.94$ -1.83
Diluted EPS
$ -2.09$ -2.30$ -1.80$ -1.94$ -1.83
Weighted Average Shares Outstanding
156.93M 143.15M 135.82M 120.37M 101.06M
Weighted Average Shares Outstanding (Diluted)
156.93M 143.15M 135.82M 120.37M 101.06M
Currency in USD

Allogene Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis